Literature DB >> 19073736

Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Yasushi Akahori1, Kazuhiro Suzuki, Tohru Daikoku, Masae Iwai, Yoshihiro Yoshida, Yoshizo Asano, Yoshikazu Kurosawa, Kimiyasu Shiraki.   

Abstract

Varicella-zoster virus (VZV) glycoprotein H (gH) is the major neutralization target of VZV, and its neutralizing epitope is conformational. Ten neutralizing human monoclonal antibodies to gH were used to map the epitopes by immunohistochemical analysis and were categorized into seven epitope groups. The combinational neutralization efficacy of two epitope groups was not synergistic. Each epitope was partially or completely resistant to concanavalin A blocking of the glycomoiety of gH, and their antibodies inhibited the cell-to-cell spread of infection. The neutralization epitope comprised at least seven independent protein portions of gH that served as the target to inhibit cell-to-cell spread.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073736      PMCID: PMC2643753          DOI: 10.1128/JVI.02097-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen.

Authors:  K Shiraki; Y Hayakawa; H Mori; J Namazue; A Takamizawa; I Yoshida; K Yamanishi; M Takahashi
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

2.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

3.  Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts.

Authors:  Kimiyasu Shiraki; Yoshihiro Yoshida; Yoshizo Asano; Koichi Yamanishi; Michiaki Takahashi
Journal:  J Infect Dis       Date:  2003-12-08       Impact factor: 5.226

4.  A human monoclonal antibody against varicella-zoster virus glycoprotein III.

Authors:  T Sugano; T Tomiyama; Y Matsumoto; S Sasaki; T Kimura; B Forghani; Y Masuho
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

5.  Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII).

Authors:  E A Montalvo; C Grose
Journal:  Virology       Date:  1986-03       Impact factor: 3.616

6.  Virus particles and glycoprotein excreted from cultured cells infected with varicella-zoster virus (VZV).

Authors:  K Shiraki; M Takahashi
Journal:  J Gen Virol       Date:  1982-08       Impact factor: 3.891

7.  Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV).

Authors:  K Shiraki; T Okuno; K Yamanishi; M Takahashi
Journal:  J Gen Virol       Date:  1982-08       Impact factor: 3.891

8.  Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.

Authors:  S A Tilley; W J Honnen; M E Racho; T C Chou; A Pinter
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

9.  Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE.

Authors:  Tracy Jo Pasieka; Lucie Maresova; Kimiyasu Shiraki; Charles Grose
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes.

Authors:  P M Keller; B J Neff; R W Ellis
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

View more
  5 in total

1.  Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency.

Authors:  Kimiyasu Shiraki; Tohru Daikoku; Masaya Takemoto; Yoshihiro Yoshida; Kazuhiro Suzuki; Yasushi Akahori; Toshiomi Okuno; Yoshikazu Kurosawa; Yoshizo Asano
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection.

Authors:  Marius Birlea; Gregory P Owens; Emily M Eshleman; Alanna Ritchie; Igor Traktinskiy; Nathan Bos; Scott Seitz; Yevgeniy Azarkh; Ravi Mahalingam; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

3.  Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Authors:  Nicole L Sullivan; Morgan A Reuter-Monslow; Janet Sei; Eberhard Durr; Carl W Davis; Cathy Chang; Megan McCausland; Andreas Wieland; David Krah; Nadine Rouphael; Aneesh K Mehta; Mark J Mulligan; Bali Pulendran; Rafi Ahmed; Kalpit A Vora
Journal:  J Virol       Date:  2018-06-29       Impact factor: 6.549

4.  A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL.

Authors:  Yi Xing; Stefan L Oliver; TuongVi Nguyen; Claudio Ciferri; Avishek Nandi; Julie Hickman; Cinzia Giovani; Edward Yang; Giuseppe Palladino; Charles Grose; Yasushi Uematsu; Anders E Lilja; Ann M Arvin; Andrea Carfí
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

5.  Defensive Perimeter in the Central Nervous System: Predominance of Astrocytes and Astrogliosis during Recovery from Varicella-Zoster Virus Encephalitis.

Authors:  John E Carpenter; Amy C Clayton; Kevin C Halling; Daniel J Bonthius; Erin M Buckingham; Wallen Jackson; Steven M Dotzler; J Patrick Card; Lynn W Enquist; Charles Grose
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.